Delivery Order SPE2DR25D1103-SPE2DR26FE151
- Not listed
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,139.18 for Shingrix vial kits on May 14, 2025, with an ultimate completion date of May 15, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (designated SPE2DX), valued at $999,999,999.00 and extending through December 2026. The...
- The Defense Logistics Agency awarded a delivery order valued at $2,278.36 to AmerisourceBergen Drug Corp for Shingrix vial kits on July 16, 2025, with completion targeted for July 17, 2025. This competitively awarded, firm fixed price delivery order represents a small-value pharmaceutical procurement executed through AmerisourceBergen's existing contract vehicle with DLA. The work will be performed at the contractor's corporate office in Conshohocken, Pennsylvania. Shingrix is a recombinant...
- The Defense Logistics Agency awarded a delivery order valued at $3,417.54 to AmerisourceBergen Drug Corp for Shingrix vial kits on July 28, 2025, with completion expected by July 29, 2025. The contract is a firm fixed-price delivery order with no set-aside designation, indicating competitive award. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the prime contractor and will perform the work at its corporate office location. Shingrix is a recombinant zoster vaccine used...
- The Defense Logistics Agency awarded a $15,032.22 delivery order to AmerisourceBergen Drug Corp for Shingrix vial kits, with an ultimate completion date of April 25, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and extending through December 2026. The place of performance is listed as Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $11,389.57 to supply Shingrix vial kits with an ultimate completion date of December 5, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. Shingrix is a recombinant zoster vaccine used for the prevention of herpes zoster (shingles) and is a critical pharmaceutical product...
- The Defense Logistics Agency awarded a delivery order valued at $3,417.54 to AmerisourceBergen Drug Corp for Shingrix vial kits, a vaccine product for the prevention of herpes zoster (shingles) in adults. The contract was awarded on September 4, 2025, with an ultimate completion date of September 5, 2025, and is structured as a firm fixed-price delivery order with no set-aside designation. Performance will be completed at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Shingrix vial kits valued at $19,434.63 on December 8, 2025, with completion expected by December 9, 2025. This firm fixed-price delivery order represents a competitively awarded contract with no set-aside designation. The work will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. Shingrix is a recombinant zoster vaccine used for the prevention of herpes zoster...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,278.36 to AmerisourceBergen Drug Corp for Shingrix vial kits, with an ultimate completion date of September 17, 2025. This competitively awarded, firm fixed-price delivery order was issued on September 16, 2025, with no set-aside designation. The contract will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. Shingrix is a recombinant zoster vaccine used for the prevention of herpes...
- The Defense Logistics Agency (DLA) awarded a $1,102.87 delivery order to AmerisourceBergen Drug Corp for Shingrix vaccine vial kits, with an ultimate completion date of November 19, 2025. This competitively awarded, firm fixed-price contract was issued on November 18, 2025, with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. Shingrix is a recombinant zoster vaccine indicated for the prevention of...
- The Defense Logistics Agency awarded a $11,391.80 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Shingrix vial kits, with a completion date of June 6, 2025. This non-set-aside contract represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.99 billion vehicle designated SPE2DX and running through December 2026. The order will be fulfilled from AmerisourceBergen's corporate office location in...
- SPE2DR25D1103Indefinite Delivery Contract
- SPE2DR25D1103-SPE2DR26FE151Delivery Order
The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $3,534.77 for Shingrix vial kits, with a completion date of December 3, 2025. This competitive award, issued December 2, 2025, represents a firm fixed price delivery order with no set-aside designation. The product will be delivered to AmerisourceBergen's corporate headquarters location in Conshohocken, Pennsylvania. Shingrix is a recombinant zoster vaccine indicated for prevention of herpes zoster and related complications in older adults and immunocompromised individuals. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. This prime contract vehicle enables AmerisourceBergen to supply a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally, including support for the Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems. The company's federal contract portfolio demonstrates its established capability to meet federal medical procurement requirements through open competition across multiple therapeutic domains and product categories.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.5k | 12/1/25 |